$CRBP News

Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026

Corbus Pharmaceuticals To Present Late Breaking Data From CRB-913 Canyon-1 Phase 1B Study At Obesity Week 2026

Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Phase 1b Topline Results for CRB-913 in Obesity and Potential as Weight Loss Therapy - Slideshow

Corbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity Study

Corbus Pharmaceuticals Shares Rise 12% After CANYON-1 Obesity Trial Data

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Phase 1b Topline Results for CRB-913 in Obesity and Potential as Weight Loss Therapy Transcript

HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $35 Price Target

Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity

Corbus Pharmaceuticals Obesity Drug Avoids 'Depressive Effects'

Corbus Pharma Announces Topline Data From CANYON-1 Phase 1b Trial Of CRB-913 Demonstrating Statistically Significant And Clinically Meaningful Weight Loss In Obesity

Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity

Corbus Pharmaceuticals To Report Topline CANYON-1 Obesity Trial Data For CRB-913; Management Team Will Host A Conference Call Webcast On Monday, September 14 At 8:00 a.m. EDT

Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Corbus Pharmaceuticals Enters Open Market Sale Agreement With Jefferies; Co. To Offer And Sell Common Stock Up To $127.50M Through Jefferies

Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $48

HC Wainwright & Co. Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $35

Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals Q2 EPS $(1.81) Misses $(1.26) Estimate

Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity